Treatment of Breast Cancer Using Multistage Delivery of PI3K/mTOR Inhibitors

被引：0
|
作者：
Blanco, E.
Sangai, T.
Martinez, J. O.
Meric-Bernstam, F.
Ferrari, M.
机构：
[1] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P6-14-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-14-10
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
    Gonzalez-Angulo, A. M.
    Blumenschein, G. R., Jr.
    CANCER TREATMENT REVIEWS, 2013, 39 (04) : 313 - 320
  • [32] PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
    Abraham, Jame
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 51 - 68
  • [33] Development of PI3K inhibitors in breast cancer.
    Ma, Cynthia X.
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 22 - 23
  • [34] Efficacy of PI3K inhibitors in advanced breast cancer
    Verret, B.
    Cortes, J.
    Bachelot, T.
    Andre, F.
    Arnedos, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 12 - 20
  • [35] PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
    Angel Guerrero-Zotano
    Ingrid A. Mayer
    Carlos L. Arteaga
    Cancer and Metastasis Reviews, 2016, 35 : 515 - 524
  • [36] PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
    Guerrero-Zotano, Angel
    Mayer, Ingrid A.
    Arteaga, Carlos L.
    CANCER AND METASTASIS REVIEWS, 2016, 35 (04) : 515 - 524
  • [37] Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations
    Bonelli, M.
    Cavazzoni, A.
    La Monica, S.
    Galetti, M.
    Caffarra, C.
    Cretella, D.
    Saccani, F.
    Fumarola, C.
    Alfieri, R.
    Petronini, P. G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S166 - S167
  • [38] Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
    Wu, Xianbo
    Xu, Yihua
    Liang, Qi
    Yang, Xinwei
    Huang, Jianli
    Wang, Jie
    Zhang, Hong
    Shi, Jianyou
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [39] Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer
    Barra, Fabio
    Evangelisti, Giulio
    Desideri, Lorenzo Ferro
    Di Domenico, Stefano
    Ferraioli, Domenico
    Vellone, Valerio Gaetano
    De Cian, Franco
    Ferrero, Simone
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (02) : 131 - 142
  • [40] PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
    Roncolato, Felicia
    Lindemann, Kristina
    Wilson, Melina L.
    Martyn, Julie
    Mileshkin, Linda
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (10):
12345